Skip to product information
1 of 1

GeneBio Systems

Recombinant Human MEK2/MAP2K2/MKK2 Protein (GST Tag)

Recombinant Human MEK2/MAP2K2/MKK2 Protein (GST Tag)

SKU:PKSH031494

Regular price ¥99,900 JPY
Regular price Sale price ¥99,900 JPY
Sale Sold out
Shipping calculated at checkout.

Size: 50μg

Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Exp date: 12 months

Category ID_II: Recombinant Proteins

Category ID_III: Others

Abbreviation:

Target Synonym: CFC4;FLJ26075;MAPKK2;MEK2;MKK2;PRKMK2

Research Areas: Signal Transduction;Cancer;

Conjugation:

Target Species: Human

Expression Host: Baculovirus-Insect Cells

Application:

Fusion tag: N-GST

UNIProt ID: P36507

Accession: NP_109587.1

Background: Dual specificity mitogen-activated protein kinase kinase 2, also known as MAP kinase kinase 2, MAPKK2, ERK activator kinase 2, MAPK / ERK kinase 2, MEK2 and MAP2K2, is a member of the protein kinase superfamily, STE Ser/Thr protein kinase family and MAP kinase kinase subfamily. MAP2K2 / MEK2 contains oneprotein kinase domain. MEK1 and MEK2 (also known as MAP2K1 and MAP2K2, respectively) are evolutionarily conserved, dual-specificity kinases that mediate Erk1 and Erk2 activation during adhesion and growth factor signaling. MAP2K1 / MEK1 is a crucial modulator of Mek and Erk signaling and have potential implications for the role of MEK1 and MEK2 in tumorigenesis. MAP2K2 / MEK2 catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. It also activates the ERK1 and ERK2 MAP kinases. Defects in MAP2K2 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) which is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy.

Concentration:

Activity: Not validated for activity

Sequence: Met 1-Val 400

Purity: > 92 % as determined by reducing SDS-PAGE.

Formulation: Lyophilized from sterile 20mM Tris, 500mM NaCl, 2mM GSH, pH 7.4
Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.

Reconstitution: Please refer to the printed manual for detailed information.

Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.

Calculated MW: 70.7 kDa

ObservedMW: 66 kDa

View full details